CD274 and neoplasm: Clinical trials for these drugs showed that the level of PD-L1 immunostaining in tumor cells or tumor-infiltrating lymphocytes determined using specific clones such as 22C3, 28–8, SP263, and SP142, was correlated with drug efficacy and patient survival rate [11, 12].